Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

41.29 +1.49 (+3.74%)
Streaming Delayed Price Updated: 10:26 AM EDT, Sep 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Veracyte Announces Second Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces First Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Completes Acquisition of C2i Genomics
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
From Veracyte, Inc.
Via Business Wire
News headline image
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Third Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Stephens Annual Investment Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
From Veracyte, Inc.
Via Business Wire
News headline image
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
From Veracyte, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.